Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 1:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Idiopathic Parkinson Disease Clear all
Active, not recruiting Phase 3 Interventional

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVN424 75 mg, CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aliso Viejo, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)

NCT03305809
View directory record Official record
Conditions
Lewy Body Dementia
Interventions
LY3154207, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years to 85 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 8, 2026, 1:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 8, 2026, 1:42 AM EDT
Withdrawn Phase 2 Interventional

Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA

NCT05103618
View directory record Official record
Conditions
Parkinson Disease, Idiopathic Parkinson Disease
Interventions
[F-18] Fluorodopa Positron Emission Tomography, OM Meditation
Drug · Behavioral
Lead sponsor
Andrew Newberg
Other
Eligibility
25 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 8, 2026, 1:42 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830
View directory record Official record
Conditions
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions
NEU-411, Placebo
Drug · Other
Lead sponsor
Neuron23 Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
45
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02240030
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301 Low Dose, CVT-301 High Dose, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 8, 2026, 1:42 AM EDT
Completed No phase listed Observational

MER Versus MRI Guidance DBS in Parkinson's Disease

NCT01883973
View directory record Official record
Conditions
Idiopathic Parkinson's Disease (PD)
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

NCT04506073
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug
Lead sponsor
Mya Schiess
Other
Eligibility
50 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 1 Interventional

Continuously Infused Intracerebral (IC) Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) for the Treatment of Idiopathic Parkinson's Disease

NCT00006488
View directory record Official record
Conditions
Parkinson Disease
Interventions
recombinant-methionyl human glial cell line-derived neurotrophic factor
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 8, 2026, 1:42 AM EDT
Recruiting No phase listed Observational

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

NCT04991831
View directory record Official record
Conditions
Tremor Associated With Tremor Dominant Parkinson's Disease
Interventions
Unilateral thalamotomy
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease

NCT02373072
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
PF-06649751, Trimethobenzamide Hydrochloride, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

NCT01777555
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Not applicable Interventional Results available

Voice Treatment for Parkinson's Disease

NCT03700684
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
Lee Silverman Voice Treatment, SpeechVive, Control
Behavioral · Device
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
West Lafayette, Indiana • Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Not applicable Interventional

Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease

NCT05862649
View directory record Official record
Conditions
Parkinson Disease
Interventions
NeuraLight
Other
Lead sponsor
NeuraLight
Industry
Eligibility
40 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 8, 2026, 1:42 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Spectroscopy in Parkinson Disease

NCT01005030
View directory record Official record
Conditions
Parkinson Disease
Interventions
Blood draw
Other
Lead sponsor
Molecular Biometrics, Inc.
Industry
Eligibility
46 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2009 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

NCT00985517
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CERE-120: Adeno-Associated Virus Delivery of Neurturin, Sham Surgery
Biological · Procedure
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
35 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 2 Interventional

The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

NCT00163085
View directory record Official record
Conditions
Parkinson's Disease
Interventions
NR2B NMDA Antagonist CP-101,606 (traxoprodil)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 22, 2006 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

NCT00474058
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 1 Interventional

A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

NCT05924243
View directory record Official record
Conditions
Parkinson Disease
Interventions
RO7486967, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 3 Interventional

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

NCT00627640
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinimide 50-100 mg/day, Matching Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00505687
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Fort Wayne, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 8, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

NCT02610231
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Istradefylline 20 mg or 40 mg
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
30 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 8, 2026, 1:42 AM EDT